Background: Traditional Chinese medicine (TCM) syndromes (ZHENG in Chinese) are the abstraction from the comprehensive analysis of clinical information gained by the four main diagnostic TCM methods: observation, listening, questioning, and pulse analyses. Proper TCM diagnosis is the most important principle to guide the prescribing of Chinese herbs. Objective: To evaluate the specific effect of TCM ZHENG on tumor growth and to examine the molecular mechanisms underlying ZHENG and tumor growth. Methods: The authors established subcutaneous tumor models of pancreatic cancer ZHENG syndromes of Damp heat (Shi-Re) and Spleen deficiency (Pi-Xu). Tissue samples of the subcutaneous transplanted tumors from each model were studied versus control tumors. CCR5 and CXCR4 proteins in these tissues were assayed by immunohistochemical staining. The expression of CCR5/CCL5/CCL4/CCL3 and CXCR4/SDF-1 mRNA was investigated by reverse transcriptase-polymerase chain reaction (RT-PCR). SDF-1, CCL4, CCL5, and CCL3, which are ligands of CXCR4 and CCR5, were examined by ELISA. Results: The study found that tumor models with different ZHENG were successfully established in each group; the tumor growth of Shi-Re group was slower than that of the control group. It was found that there was a significant difference in CCR5 mRNA expression levels among the Pi-Xu, Shi-Re, and control groups. The results of immunohistochemistry staining revealed that the positive rate of CCR5 protein in Shi-Re group, Pi-Xu group, and control group was 25.00%, 53.33%, 83.33%, respectively. The Shi-Re group expressed the lowest levels of CCL5 and CCL4. Conclusion: The results of the study suggest that the existence of TCM ZHENG may influence the tumor growth in pancreatic cancer, which might be mediated by the expression of CCR5/CCL5/CCL4. This finding may lead to the development of TCM ZHENG as a prognostic indicator in pancreatic tumor growth.
Introduction
Traditional Chinese medicine (TCM) is a system with its own rich tradition and collection of data from more than 3,000 years of continuous use and improvement. As one form of complementary medicine, TCM was used by about 1.5 billion people all over the world in 2005. 1 A recent report has shown that herbal medicine used among cancer patients was the most common complementary therapy in Europe. 2 TCM is characterized by regulating the integrity of human body by using herbal formulas for managing com plicated ZHENG (TCM syndromes). With strong emphasis on the comprehensive analysis of clinical information colle cted by observation, listening, questioning, and pulse analyses, ZHENG is the basis of understanding the disorders of patients and guiding the use of the Chinese herbs. However, when TCM meets biomolecular science and Westernbased medicine, the validity and the biomolecular role of ZHENG is poorly understood.
In recent years, the basic concepts in Western medicine for treating cancer have changed dramatically based on a better understanding of cancerrelated molecular pathways. With the advent of targeted therapy, which is based on indi vidual patient tumor characteristics, different targeted agents may be needed in patients with a similar tumor type and with a similar pathological subtype, based on the differen tial expression of tumor proteins. On the other hand, patients with different tumor types may receive a similar targeted agent if their tumors express the same tumor protein pro files. Modern oncology has entered the era of personalized therapy. Under the guidance of ZHENG diagnosis in TCM, patients with the same tumor and different ZHENG should be treated by different herbs, and patients with different tumors and the same ZHENG should be treated by the same herbs. Both the theories of "the same treatment for the same ZHENG" and "the same treatment for the same therapeutic target" indicate that personalized therapy in Western medi cine is similar to treatment in TCM using ZHENG syndrome diagnosis. But, so far, we have no biological evidence to support the validity of ZHENG. 3 Owing to the importance of ZHENG in both the theory and the practice of TCM, it is important to examine the medical fundamentals of ZHENG. Research in metastatic gastric carcinoma found that the types of stasis and endog enous toxics and the discordance of liver-stomach was associated with the loss of Ecadherin expression. 4 Another study concluded that the earlier stages of chronic atrophic gastritis was mainly characterized by ZHENG of blood stasis and poison heat, the middle period of chronic atro phic gastritis patients was mainly ZHENG of yin deficiency and heat, and the late stage was mainly ZHENG of qi and yin. The pathology variation might be related to ZHENG types of TCM in chronic atrophic gastritis patients. 5 In spite of all these initial efforts, there is still not a clear under standing of the biological validity of ZHENG and the possible mechanisms of ZHENG in cancer.
There has been no previous research examining the bio logical activity of ZHENG in pancreatic cancer. From a TCM syndrome perspective, Shi-Re and Pi-Xu (Damp heat and Spleen deficiency, respectively) are the most common types of TCM ZHENG diagnosed in pancreatic cancer. 6 The association between different ZHENG in the prognosis or bio logical characteristics of pancreatic cancer has never been explored. Here, we first propose a novel model of "ZHENGsubcutaneous transplanted tumor" and then explore the pot ential molecular basis of ZHENG within the context of chemokines and there receptors in pancreatic cancer.
Materials and Methods

Cell Lines and Mice
Pancreatic cancer cell lines panc02 were obtained from the Cancer Research and Development Center and grown in complete growth medium as recommended by the manufacturer. All of the cultured cells were maintained in DMEM (Dulbecco's modified Eagle medium; Gibco Biocult, Paisley, UK), supplemented with 10% calf bovine serum (Sijiqing Biotechnology, Hangzhou, China), 100 U/mL penicillin, and 100 mg/mL streptomycin (North China Phar maceutical Group Corporation, Shijiazhuang, China) at 37°C and 5% CO 2 .
Male C57 mice 4 to 6 weeks old were obtained from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Shanghai, China), and housed in laminar flow cabinets under specific pathogen free conditions with food and water ad libitum. All experiments on mice were con ducted in accordance with the guidelines of the National Institutes of Health for the Care and Use of Laboratory Ani mals. The study protocol was also approved by the Shanghai Medical Experimental Animal Care Committee.
Agents to Create Shi-Re, Pi-Xu
Decoction of mirabilite and Chinese rhubarb: A mixture of mirabilite (mineral) and Chinese rhubarb herb at a ratio of 1 to 4, with a final concentration of the decoction of 1 g/mL.
Honey (GuanShengYuan): The concentration is 20%; wine (HongXing, ErGuoTou, Beijing): regulate the concentration to be 55% by water; grease of pig: donated by Gu JianZhong, Chinese Academy of Sciences (Shanghai, China).
Methods
A total of 36 C57 mice were assigned at random to 3 groups, 12 mice in each group.
TCM ZHENG model. We developed a model of Shi-Re, Pi-Xu, and also had a control group (nonZHENG group). Pi-Xu was developed by feeding the mice with a decoction of mirabilite and Chinese rhubarb; 0.2 mL for each mouse (day 1 to day 7). Shi-Re was developed by the wine and the grease combination (day 1 to day 7, 0.2 mL), the food and honeywater were provided. 7, 8 Mice in the control group were given equal volume of natural saline. Subcutaneous xenograft cancer model. Cultured tumor cells, 2 × 10 6 cells in 0.2mL freeserum medium, were injected subcutaneously into the right axilla of each mouse. Tumor growth was measured by tumor diameters with a Vernier caliper twice a week from the 10th day till the 30th day after tumor inoculation and growth curves were made. Tumor volume (TV) was calculated according to the for mula: TV (mm 3 ) = d 2 × D × 1/2, where d and D represent the shortest and the longest diameter, respectively. At the end of the experiment, mice were sacrificed and tumors were removed and weighted.
Tissue samples of subcutaneous transplanted tumors were then analyzed for specific tumor characteristics.
RT-PCR analysis. Total RNA was isolated from tissues using the TRIzol reagent (Invitrogen, San Diego, CA) according to the manufacturer's instructions. Reverse transcriptionpolymerase chain reaction (RTPCR) using SYBR green I to compare the relative expression of specific gene messenger RNA was done as described in an earlier publication. 9 Immunohistochemical staining. In brief, specimens of the subcutaneously implanted xenograft tumors were fixed in formalin, embedded in paraffin and cut into 3mm sections. The sections were then deparaffinized in xylene and etha nol, placed in 0.1 mol/L citrate buffer (pH 6.0) and irradiated with microwaves (750 W) for 15 minutes. The sections were then incubated with primary antibodies for CXCR4 (chemokine CXC motif receptor, goat monoclonal, dilu tion 1:100; Santa Cruz Laboratory, Santa Cruz, CA) and CCR5 (CC chemokine 5, goat monoclonal, dilution 1:300; Santa Cruz Laboratory, Santa Cruz, CA). The sections were incubated for 1 hour at room temperature with the first anti body, rinsed 5 times with phosphatebuffered saline (PBS), and then incubated with peroxidaseconjugated antimouse/ goat immunoglobulins (DAKO EnVisionTM System; Dako Corporation, Carpinteria, CA). The sections were then deve loped with 3,3′diaminobenzidine tetrahydrochloride and counterstained with hematoxylin.
All immunostained sections were evaluated independen tly by 2 investigators without knowledge of the background of the study. A total of 10 fields (inside the tumor and in the area exhibiting tumor invasion) were selected, and expres sion was evaluated in 1000 tumor cells (100 cells per field) with high power (×200) microscopy. The evaluations were recorded as the percentage of positively stained tumor cells in each of three intensity categories. A consensus judgment was adopted as to the proper immu nohisto chemical score of the tumors based on the strength of CXCR4 expression: negative, weak staining, moderate staining, or strong stain ing. In the present study, the distribution of positive cells was also recorded to portray the diffuse or focal nature of the positive cells: sporadic (positive cells <5%); focal (pos itive cells >11% but less than 50%); or diffuse (positive cells >50%). Samples with immunohistochemical scores of negative, weak, or moderate staining with sporadic to focal dis tributions were con sidered to have "low" expres sion whereas diffuse distributions were considered to have "high" expression for target antibodies.
ELISA. The concentration of CXCL12 (stromalderived factor1 or SDF1), CCL5 (regulation and activation, normal T cell expression and secretion of RANTES), CCL4 (macrophage inflammatory protein1b) and CCL3 (macrophage inflamma tory protein1a, MIP1a) in the tumor samples was determined using a sandwich ELISA kit (DuoSet; R&D Systems, Minne apolis, MN) according to the protocol of the manufacturer.
Statistical Analyses
Pearson c 2 , Student's t test, Satterthwaite's t test, and Wil coxon signedrank test were used to determine the statistical significance for differences between the experimental groups. Statistical significance was defined as P < .05.
Results
We first determined the establishment of the different ZHENG models of Shi-Re ZHENG and Pi-Xu ZHENG. Pi-Xu ZHENG was evidenced by lassitude, preference for warmth and into lerances to cold, having cold extremities, and loose stool. Mice in the Shi-Re group showed emaciated constitution, heaviness in the limbs, poor appetite, and dry and hard stool. No specific symptoms were found among mice in control group. Figure 1 shows the growth curves of the tumors from the 3 groups. Tumor growth in Shi-Re group was significantly slower than in control group. The trend of tumor growth in Pi-Xu group was also slower than in the control group. There was, however, no significant difference in average volumes of tumors between the Pi-Xu group and the control group.
Tumor Growth
CCR5/CCL5/CCL4 Expression Levels Among 3 Groups
To assess the relationship between CXCR4/SDF1 expres sion and tumor growth with different ZHENG in pancreatic cancer, immunohistochemical staining and RTPCR were done to investigate the expression of protein levels of CXCR4 and mRNA levels of CXCR4 and SDF1. The results showed the expression of CXCR4/SDF1 were not statistically sig nificantly different among the groups (Figures 2C and 2D , Figure 3B , and Figure 4A ). Therefore CXCR4/SDF1 axis may have no direct correlation with ZHENG in tumor growth of pancreatic cancer.
To determine the expression of CCR5 in tumors with dif ferent TCM ZHENG, we first used RTPCR to examine mRNA expression of CCR5, CCL3, CCL4 and CCL5 of tumors from the Shi-Re, Pi-Xu, and control groups ( Figure 4A ). As shown in Figure 4B , we found that there was a significant difference in mRNA CCR5 expression among tumors from the Pi-Xu, Shi-Re, and control groups (control group vs Pi-Xu group, P = .0217; Shi-Re group vs control group, P = .0041). mRNA levels of CCL3, CCL4, and CCL5 were not different among the groups. We also performed immuno histochemical staining to investigate CCR5 protein in the representative target tissues from each group. In accordance with the results from RTPCR, we observed strong staining of CCR5 in the control group and tumors from Shi-Re group expressed low levels. As shown in Figure 2A and B, Figure 3A , the positive rate of CCR5 protein in Shi-Re group, Pi-Xu group, and control group was 25.00%, 53.33%, 83.33%, res pectively (Shi-Re group vs control group, P = .012).
We also examined the expression of CCR5 on the local concentration of CCL3, CCL4 and CCL5 detected by ELISA ( Figure 5 ). We observed that the Shi-Re group exp ressed the lowest levels of CCL5 and CCL4 (CCL5: control group vs Pi-Xu group, P = .062, Shi-Re group vs control group, P = .0000; Pi-Xu group vs Shi-Re group, P = .0029. CCL4: control group vs Pi-Xu group, P = .0007; Shi-Re group vs control group, P = .0000; Pi-Xu group vs Shi-Re group, P = .0023). These data, taken together, showed that expression of CCR5/CCL4/CCL5 axis was associated with TCM ZHENG in pancreatic tumor growth.
Discussion
TCM is a popular complementary treatment among cancer patients. Pancreatic cancer patients often seek TCM to sup plement or replace chemotherapy and radiotherapy, especially in Asian countries. Almost all studies on TCM focus on the efficacy and safety of herb products, with many clinical trials suggesting a potentially beneficial role of Chinese herbs in cancer treatment, and a positive effect on quality of life without any consideration of ZHENG of the patients. 10, 11 Although ZHENG helps guide the application of the Chi nese herbs, it has not been well studied. Recently, some studies suggest that ZHENG is related to the concept evolv ing in modern oncology of personalized medicine, 12 but there is still no evidence to support the personalized approach. ZHENG is the therapeutically basic concept in TCM for understanding the disorders of human homeostasis and guiding application of Chinese herbs, yet there is no formal validation for this process. 13 For most doctors, the lack of understanding of ZHENG becomes a restriction for TCM development and even understanding of TCM. 14 Understand ing the potential molecular mechanisms underlying ZHENG and tumor growth thus becomes important.
We established subcutaneous tumor models of pancre atic cancer for TCM ZHENG Shi-Re ZHENG and Pi-Xu ZHENG to investigate tumor growth among each group and explore the potential molecular mechanisms underly ing ZHENG and tumor growth. As we know, each tumor has some different characteristics while also sharing the same course of disease development and similar physio logical, pathological, and biochemical changes. ZHENG can be seen as the TCM theoretical abstraction of a symp tom profile of a disease. Also, ZHENG can be used as a guideline for disease classification in TCM and to guide herbal prescribing. Patients suffering from pancreatic cancer may be categorized into different ZHENG, such as Shi-Re ZHENG and Pi-Xu ZHENG. 6 TCM ZHENG can also change during pancreatic cancer progression. In this study, we established subcutaneous tumor models with dif ferent ZHENG for pancreatic cancer to evaluate the specific significance of ZHENG on pancreatic tumor growth and provided the necessary understanding and background of ZHENG.
During the study, we were able to control a number of factors that can influence ZHENG such as age, gender, weight, tumor cells, and so on. The only difference between these mice was the ZHENG induced by the different treatments. Paget 14 suggests that the sites where metastases occur are defined not only by the tumor cell ("seed," panc02 cells in this study) but also the microenvironment of the metastatic site ("soil," in this case the mice with different ZHENG). We found that tumor growth in the ZHENG groups was slower than in the control group, suggesting that the exis tence of ZHENG may affect tumor growth in murine cancer models. Thus, inducing different ZHENG in these animal models may result in the organism antagonizing the tumor growth. The regulation of tumor growth is likely to vary with each individual ZHENG, which means in pancreatic cancer, ZHENG might be related to microenvironment of Westernbased medicine. Our findings suggest that ZHENG can influence tumor growth and further study is warranted.
Numerous factors in the microenvironment have been found to play an important role in the development of cancer and influencing growth once established. Chemokines and their receptors, including CXCL12 (stromalderived factor1 [SDF1])/CXCR4 (chemokine CXC motif receptor 4), CCL4 (MIP1b), CCL3 (macrophage inflammatory protein 1a, MIP1a), CCL5 (regulation and activation, normal T cell expression and secretion of RANTES), and CCR5 (CC chemokine 5) are all critical in modulating the tumor micro environment. 1517 CXCL12 and its receptor CXCR4 have been demonstrated to play a significant role in a broad array of tissues and organs. 18, 19 Recent studies have indicated that CXCL12/CXCR4 were related to the adhesion, invasion, and proliferation of pancreatic cancer cells 20 and survival of pancreatic cancer patients. 21 CCR5 is a promiscuous recep tor, which binds with high affinity to CCL5, CCL3 and CCL4. CCL5 is also a key regulator of Tcell migration to inflammatory sites, and is considered mainly as an inflam matory mediator, directing the migration of T cells. 22, 23 CCR5 mediates cell responses to CCL5 in cells that express the receptor, such as monocytes and macrophages. CCR5/ CCL5 has been demonstrated to play important roles in microenvironment. The research on CCR5/CCL3/CCL4/ CCL5 in tumor development is just beginning. In mela noma, breast and pancreatic cancers, 2426 there is preliminary evidence for the role of CCL5/CCR5 axis in these diseases. In other cancer types, the findings are also descriptive, pro viding a few hints of the possible activities of CCL5 and CCR5 in disease progression.
As mentioned above, a number of studies have examined the importance of CCR5 and CXCR4 in the microenviron ment of tumor progression. Pancreatic carcinoma is known to overexpress these chemokines and their corresponding highaffinity receptors. 20, 26 However, the association between these molecules and how they related to ZHENG in pancre atic cancer has not been evaluated. If ZHENG does influence tumor growth in pancreatic cancer, then these chemokines and there receptors may be a possible direct or indirect mech anism for ZHENG's effects on tumor growth.
In our study, we first found tumor growth in Shi-Re group was significantly slower than in control group. The trend of tumor growth in Pi-Xu group was also slower than in the control group. We speculated that ZHENG could influence the tumor growth in pancreatic cancer and ZHENG may have a relationship with microenvironment based on theory of "seed and soil." Therefore, we emphasized the mentioned above biological axis and found differential expression of CCR5 but not CXCR4/SDF1 between the 3 groups. In addition, local concentrations of CCL5 and CCL4 were the lowest in the Shi-Re group when compared with the other 2 groups. Tumors in the Shi-Re group had the slowest growth and expressed the lowest levels of CCR5, CCL5, and CCL4; whereas the tumors in the control group had the fastest growth and expressed the highest levels of CCR5, CCL5, and CCL4. In breast cancer, increased levels of CCL5 were found in patients with disease progression. 27, 28 Similar results were also observed in melanoma and ovarian cancer. 29, 30 Here, we have no direct evidence to demonstrate CCR5 axis promote the tumor growth in control group. But we indicate that CCR5/CCL5/CCL4 may be an important mediator in pancreatic tumor growth associated with Shi-Re ZHENG, Pi-Xu ZHENG, and NonZHENG. Here, we just present a novel mechanism of ZHENG on tumor growth via regula tion CCR5/CCL5/CCL4. Further research is needed to exp lore the mechanisms of ZHENG in TCM.
Conclusion
We attempted to examine an unspecific effect of ZHENG in pancreatic tumor growth. Our study suggested that the exis tence of TCM ZHENG may influence the tumor growth in pancreatic cancer which might be mediated by the expres sion of CCR5/CCL5/CCL4. This finding may lead to a new significance of ZHENG as a prognostic indicator in pancre atic tumor growth.
Declaration of Conflicting Interests
The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article. 
